Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bridget Silverman
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Around the world, government agencies, academic and other researchers and the biopharmaceutical industry have rushed to see what drugs could help treat COVID-19 and the symptoms it causes, and accelerate a vaccine that could help limit the spread of the pandemic. This chart will be updated daily as additional research gets underway.
Updated daily as additional research gets underway, this pipeline tracker follows the global effort to find drugs that could help treat COVID-19 and the symptoms it causes, and accelerate a vaccine that could help limit the spread of the pandemic.
First COVID-19 experimental treatment trial in US is a master protocol that echoes NIH’s Ebola treatment approach.
Epidemiology complicates field efficacy trials, but US FDA advisory committee members regretfully agree that data from non-human primate passive transfer studies is compelling but potentially insufficient for chikungunya vaccines.